Impact of myeloid cells on the adaptive immune response in newly diagnosed and recurrent glioblastomas (B04)

• Subject Area: Hematology, Oncology
• Term: since 2019
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 404521405

In the last funding period, we observed profound differences in the efficacy of drugs targeting the tumor microenvironment (TME) of gliomas. Therefore, this project aims at studying larger series of TME-targeting drugs on patient-derived glioblastoma organoids in a high throughput format on the global, spatial, single cell and functional level by multi-omics and bioinformatic analysis. This will help to predict effectiveness of TME-targeting drugs on a patient-individual level and to develop a platform for the future personalized testing of TME-targeting drugs alone or in combination with other types of treatment in glioblastoma.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1389: Understanding and Targeting Resistance in Glioblastoma (UNITE Glioblastoma)
• Applicant Institution: Ruprecht-Karls-Universität Heidelberg
• Project Heads: Professorin Dr. Christel Herold-Mende; Dr. Rolf Warta